Literature DB >> 22391086

Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis.

Frank W Virgin1, Steven M Rowe, Mary B Wade, Amit Gaggar, Kevin J Leon, K Randall Young, Bradford A Woodworth.   

Abstract

BACKGROUND: Chronic rhinosinusitis has a major impact on the quality of life of patients with cystic fibrosis (CF) and may contribute to progression of chronic lung disease. Despite multiple sinus surgeries, maxillary sinus involvement is a recurrent problem. The modified endoscopic medial maxillectomy (MEMM) permits debridement in the clinic, improves mucus clearance with nasal irrigations, and increases access for topical delivery of therapeutics. However, clinical outcomes of aggressive sinus surgery with regimented postoperative medical treatment have not been systematically evaluated.
METHODS: CF patients completed the 22-Item Sinonasal Outcome Test questionnaires before sinus surgery (and bilateral MEMM) and at sequential postoperative visits. Objective measures included Lund-Kennedy endoscopic score and pulmonary function tests (forced expiratory volume at 1 second percent [FEV(1)%] predicted). Culture-directed antibiotic therapy, prednisone, and topical irrigations were initiated postoperatively.
RESULTS: Twenty-two patients (mean age, 26.5 years; 4.9 prior sinus operations) underwent MEMM and sinus surgery. Symptom scores were significantly reduced at 60 days (primary outcome, 64.7 ± 18.4 presurgery versus 27.5 ± 15.3 postsurgery; p < 0.0001) and up to a year postoperatively (27.6 ± 12.6; p < 0.0001). Endoscopic scores were also reduced after surgery (10.4 ± 1.1 presurgery versus 5.7 ± 2.4 [30 days], 5.7 ± 1.4 [60 days], 5.8 ± 1.3 [120 days], and 6.0 ± 1.1 [1 year]; p < 0.0001)]. There were no differences in FEV(1)% predicted up to 1 year postoperatively, but hospital admissions secondary to pulmonary exacerbations significantly decreased (2.0 ± 1.4 versus 3.2 ± 2.4, respectively; p < 0.05).
CONCLUSION: Prospective evaluation indicates sinus surgery with MEMM is associated with marked improvement in sinus disease outcomes. Additional studies are necessary to confirm whether this treatment paradigm is associated with improved CF pulmonary disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391086      PMCID: PMC3622282          DOI: 10.2500/ajra.2012.26.3705

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  33 in total

1.  Patterns of sinusitis in cystic fibrosis.

Authors:  V G Gentile; G Isaacson
Journal:  Laryngoscope       Date:  1996-08       Impact factor: 3.325

2.  Cystic fibrosis.

Authors:  Steven M Rowe; Stacey Miller; Eric J Sorscher
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

3.  Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis requiring surgery.

Authors:  T T Kingdom; K C Lee; S C FitzSimmons; G J Cropp
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-11

4.  Long-term results of functional endoscopic sinus surgery.

Authors:  B A Senior; D W Kennedy; J Tanabodee; H Kroger; M Hassab; D Lanza
Journal:  Laryngoscope       Date:  1998-02       Impact factor: 3.325

5.  Effect of sinus surgery on pulmonary function in patients with cystic fibrosis.

Authors:  D Madonna; G Isaacson; R M Rosenfeld; H Panitch
Journal:  Laryngoscope       Date:  1997-03       Impact factor: 3.325

Review 6.  Management of sinusitis in the asthmatic patient.

Authors:  B A Senior; D W Kennedy
Journal:  Ann Allergy Asthma Immunol       Date:  1996-07       Impact factor: 6.347

7.  Indications for sinus surgery: how appropriate are the guidelines?

Authors:  J F Piccirillo; S E Thawley; A Haiduk; M Kramper; M Wallace; J M Hartman
Journal:  Laryngoscope       Date:  1998-03       Impact factor: 3.325

8.  Pathological changes of the lateral nasal wall in patients with cystic fibrosis (mucoviscidosis).

Authors:  P Brihaye; P A Clement; I Dab; B Desprechin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1994-01       Impact factor: 1.675

9.  Quantification for staging sinusitis. The Staging and Therapy Group.

Authors:  V J Lund; D W Kennedy
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1995-10

10.  Mucociliary clearance in patients with cystic fibrosis and in normal subjects.

Authors:  J A Regnis; M Robinson; D L Bailey; P Cook; P Hooper; H K Chan; I Gonda; G Bautovich; P T Bye
Journal:  Am J Respir Crit Care Med       Date:  1994-07       Impact factor: 21.405

View more
  24 in total

Review 1.  Comprehensive review on endonasal endoscopic sinus surgery.

Authors:  Rainer K Weber; Werner Hosemann
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

Review 2.  Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: systematic review and meta-analysis.

Authors:  Kornkiat Snidvongs; Larry Kalish; Raymond Sacks; Rahuram Sivasubramaniam; Daron Cope; Richard J Harvey
Journal:  Am J Rhinol Allergy       Date:  2013 May-Jun       Impact factor: 2.467

Review 3.  Management of the upper airway in cystic fibrosis.

Authors:  Elisa A Illing; Bradford A Woodworth
Journal:  Curr Opin Pulm Med       Date:  2014-11       Impact factor: 3.155

Review 4.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

Review 5.  Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis.

Authors:  Zachary M Soler; Rabun Jones; Phong Le; Luke Rudmik; Jose L Mattos; Shaun A Nguyen; Rodney J Schlosser
Journal:  Laryngoscope       Date:  2017-11-22       Impact factor: 3.325

Review 6.  Phenotypes of Chronic Rhinosinusitis.

Authors:  Seong H Cho; Daniel L Hamilos; Doo Hee Han; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol Pract       Date:  2020-05

7.  Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency.

Authors:  Bradford A Woodworth
Journal:  Laryngoscope       Date:  2015-05-06       Impact factor: 3.325

8.  Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.

Authors:  Do-Yeon Cho; Shaoyan Zhang; Ahmed Lazrak; Jessica W Grayson; Jaime A Peña Garcia; Daniel F Skinner; Dong Jin Lim; Calvin Mackey; Catherine Banks; Sadis Matalon; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2018-08-27       Impact factor: 3.858

9.  Smell in cystic fibrosis.

Authors:  J Lindig; C Steger; N Beiersdorf; R Michl; J F Beck; T Hummel; J G Mainz
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-08-14       Impact factor: 2.503

Review 10.  Sinus bacteriology in patients with cystic fibrosis or primary ciliary dyskinesia: A systematic review.

Authors:  Maria E Møller; Mikkel C Alanin; Christian Grønhøj; Kasper Aanæs; Niels Høiby; Christian von Buchwald
Journal:  Am J Rhinol Allergy       Date:  2017-09-01       Impact factor: 2.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.